We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Long Limb Roux-en Y Reconstruction (LoLiRoRe)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01373346
First Posted: June 14, 2011
Last Update Posted: September 3, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Seung Ho Choi, Gangnam Severance Hospital
Results First Submitted: March 11, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Diabetes Mellitus Type 2 in Nonobese
Gastric Cancer
Intervention: Procedure: Long limb Roux-en Y reconstruction

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
If Patients were eligible for the study, each patient was informed of the investigational nature of the trial and received detailed information regarding the study protocol. All patients provided written informed consent before their enrollment. The enrollment continued from February 2010 through May 2011 in Gangnam Severance Hospital.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Long Limb Roux-en Y Reconstruction Total or Subtotal gastrectomized gastric cancer patient with long limb Roux en Y reconstruction

Participant Flow:   Overall Study
    Long Limb Roux-en Y Reconstruction
STARTED   15 
COMPLETED   14 
NOT COMPLETED   1 
Death                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Long Limb Roux-en Y Reconstruction Total or Subtotal gastrectomized gastric cancer patient with long limb Roux en Y reconstruction

Baseline Measures
   Long Limb Roux-en Y Reconstruction 
Overall Participants Analyzed 
[Units: Participants]
 15 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   8 
>=65 years   7 
Age 
[Units: Years]
Mean (Standard Deviation)
 62.1  (8.7) 
Gender 
[Units: Participants]
 
Female   5 
Male   10 
Region of Enrollment 
[Units: Participants]
 
Korea, Republic of   15 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Morbidity   [ Time Frame: Until end of study (on average 14.8 months) ]

2.  Primary:   HbA1c   [ Time Frame: Before operation , 6 months after operation, Until end of study (on average 14.8 months) ]

3.  Primary:   Hemoglobin   [ Time Frame: Before operation , 6 months after operation, Until end of study (on average 14.8 months) ]

4.  Primary:   Albumin   [ Time Frame: Before operation , 6 months after operation, Until end of study (on average 14.8 months) ]

5.  Primary:   Operation Related Mortality   [ Time Frame: Until end of study (on average 14.8 months) ]

6.  Secondary:   Matsuda Index   [ Time Frame: Before operation , 6 months after operation, Until end of study (on average 14.8 months) ]

7.  Secondary:   QUICKI   [ Time Frame: Before operation , 6 months after operation , Until end of study (on average 14.8 months) ]

8.  Secondary:   HOMA-IR   [ Time Frame: Before operation , 6 months after operation, Until end of study (on average 14.8 months) ]

9.  Secondary:   HOMA-B   [ Time Frame: Before operation , 6 months after operation, Until end of study (on average 14.8 months) ]

10.  Secondary:   Body Mass Index   [ Time Frame: Before operation, 6 Months After Operation, Until End of Study(on Average 14.8 Months) ]

11.  Secondary:   Matsuda Index : Good Response Group   [ Time Frame: Before operation , 6 months after operation, Until end of study (on average 14.8 months) ]

12.  Secondary:   QUICKI : Good Response Group   [ Time Frame: Before operation, 6 months after operation, Until end of study (on average 14.8 months) ]

13.  Secondary:   HOMA-IR : Good Response Group   [ Time Frame: Before operation, 6 months after operation, Until end of study (on average 14.8 months) ]

14.  Secondary:   HOMA-B : Good Response Group   [ Time Frame: Before operation, 6 months after operation, Until end of study (on average 14.8 months) ]

15.  Secondary:   Body Mass Index : Good Response Group   [ Time Frame: Before operation, 6 months after operation, Until end of study (on average 14.8 months) ]

16.  Secondary:   HbA1c : Good Response Group   [ Time Frame: Before operation, 6 months after operation, Until end of study (on average 14.8 months) ]

17.  Secondary:   Hemoglobin : Good Response Group   [ Time Frame: Before operation, 6 months after operation, Until end of study (on average 14.8 months) ]

18.  Secondary:   Albumin : Good Response Group   [ Time Frame: Before operation, 6 months after operation, Until end of study (on average 14.8 months) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
One mortality due to early recurrence leading to reduced number of subject analyzed.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Seung Ho Choi, M.D., Ph.D.
Organization: Gangnam severance hospital
phone: 82-2-2019-3374
e-mail: choish@yuhs.ac


Publications:


Responsible Party: Seung Ho Choi, Gangnam Severance Hospital
ClinicalTrials.gov Identifier: NCT01373346     History of Changes
Other Study ID Numbers: seungho-1
First Submitted: June 13, 2011
First Posted: June 14, 2011
Results First Submitted: March 11, 2012
Results First Posted: August 31, 2012
Last Update Posted: September 3, 2012